Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Vercise™ DBS Dystonia Prospective Study

NCT: NCT02686125 · RECRUITING

NCT IDNCT02686125
StatusRECRUITING
Start Date2016-03-07
SponsorBoston Scientific Corporation (INDUSTRY)
First posted
Last updated

Brief Summary

To compile characteristics of real-world outcomes of Boston Scientific Corporation's commercially approved VerciseTM Deep Brain Stimulation (DBS) Systems for the treatment of dystonia.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑